Stereotactic Body Radiation Therapy for Inoperable Locally-advanced Non-small Cell Lung Cancer
Status:
Active, not recruiting
Trial end date:
2022-07-01
Target enrollment:
Participant gender:
Summary
The purpose of this study is to determine if the use of exploratory immunologic biomarkers,
functional MRI images can serve as early predictors for response of NSCLC. It also will
provide important information on the perceived side effects from a patient perspective.
Patients may participate if they have tumors ≥3 cm without lymph node involvement (for which
chemotherapy is not part of the standard of care). Patients will only receive stereotactic
body radiation therapy (SBRT) per standard dose guidelines.